Literature DB >> 27025351

Anti-Helicobacter pylori activity of some newly synthesized derivatives of xanthone.

Karolina Klesiewicz1, Elżbieta Karczewska1, Alicja Budak1, Henryk Marona2, Natalia Szkaradek2.   

Abstract

A series of 20 xanthone derivatives was synthesized and evaluated for anti-Helicobacter pylori (H. pylori) activity. Qualitative and quantitative in vitro tests using the Kirby-Bauer method (agar disc-diffusion method) were performed. The tested compounds were screened against clarithromycin- and/or metronidazole-resistant strains of H. pylori. As a reference, Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacterial strains were examined. On the basis of microbiological assays, xanthones can be considered as potential anti-H. pylori agents. They displayed significant activity against the examined strains, which was higher against the bacteria resistant to metronidazole than clarithromycin. The lowest MIC values ranging up to 20 mg l-1 were observed for the following compounds: 3, 4, 8, 9, 12, 19 (against the metronidazole-resistant strains) and the compound 10 (against the clarithromycin-resistant strain). These preliminary results for screening of xanthone derivatives form a part of an ongoing study of the structure-activity relationships of a large group of compounds. Microbiological assays will be conducted afterwards to determine the mechanism of xanthones' action against H. pylori.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27025351     DOI: 10.1038/ja.2016.36

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  31 in total

1.  Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report.

Authors:  Peter Malfertheiner; Francis Megraud; Colm A O'Morain; John Atherton; Anthony T R Axon; Franco Bazzoli; Gian Franco Gensini; Javier P Gisbert; David Y Graham; Theodore Rokkas; Emad M El-Omar; Ernst J Kuipers
Journal:  Gut       Date:  2012-05       Impact factor: 23.059

Review 2.  Extragastric manifestations of Helicobacter pylori infection.

Authors:  Natale Figura; Francesco Franceschi; Annalisa Santucci; Giulia Bernardini; Giovanni Gasbarrini; Antonio Gasbarrini
Journal:  Helicobacter       Date:  2010-09       Impact factor: 5.753

Review 3.  Helicobacter pylori and its involvement in gastritis and peptic ulcer formation.

Authors:  S J Konturek; P C Konturek; J W Konturek; M Plonka; M Czesnikiewicz-Guzik; T Brzozowski; W Bielanski
Journal:  J Physiol Pharmacol       Date:  2006-09       Impact factor: 3.011

4.  Synthesis and properties of some aminoalkanolic derivatives of xanthone.

Authors:  H Marona; E Szneler; B Filipek; J Sapa
Journal:  Acta Pol Pharm       Date:  1997 Jan-Feb       Impact factor: 0.330

Review 5.  Helicobacter pylori and gastric cancer: factors that modulate disease risk.

Authors:  Lydia E Wroblewski; Richard M Peek; Keith T Wilson
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

6.  Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo.

Authors:  G W Rewcastle; G J Atwell; B C Baguley; S B Calveley; W A Denny
Journal:  J Med Chem       Date:  1989-04       Impact factor: 7.446

Review 7.  Causal role of Helicobacter pylori infection in gastric cancer.

Authors:  Takafumi Ando; Yasuyuki Goto; Osamu Maeda; Osamu Watanabe; Kazuhiro Ishiguro; Hidemi Goto
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

8.  Substituted xanthones as antimycobacterial agents, Part 2: Antimycobacterial activity.

Authors:  M Pickert; K J Schaper; A W Frahm
Journal:  Arch Pharm (Weinheim)       Date:  1998-05       Impact factor: 3.751

9.  Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption.

Authors:  Francis Megraud; Samuel Coenen; Ann Versporten; Manfred Kist; Manuel Lopez-Brea; Alexander M Hirschl; Leif P Andersen; Herman Goossens; Youri Glupczynski
Journal:  Gut       Date:  2012-05-12       Impact factor: 23.059

10.  Pyranocycloartobiloxanthone A, a novel gastroprotective compound from Artocarpus obtusus Jarret, against ethanol-induced acute gastric ulcer in vivo.

Authors:  Heyam M A Sidahmed; Najihah Mohd Hashim; Junaidah Amir; Mahmood Ameen Abdulla; A Hamid A Hadi; Siddig Ibrahim Abdelwahab; Manal Mohamed Elhassan Taha; Pouya Hassandarvish; Xinsheng Teh; Mun Fai Loke; Jamuna Vadivelu; Mawardi Rahmani; Syam Mohan
Journal:  Phytomedicine       Date:  2013-04-06       Impact factor: 5.340

View more
  2 in total

1.  Irigenin, a novel lead from Iris confusa for management of Helicobacter pylori infection with selective COX-2 and HpIMPDH inhibitory potential.

Authors:  Passent M Abdel-Baki; Moshera M El-Sherei; Amal E Khaleel; Marwa M Abdel-Aziz; Mona M Okba
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

Review 2.  The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications.

Authors:  Amir Hossein Miri; Mojtaba Kamankesh; Antoni Llopis-Lorente; Chenguang Liu; Matthias G Wacker; Ismaeil Haririan; Hamid Asadzadeh Aghdaei; Michael R Hamblin; Abbas Yadegar; Mazda Rad-Malekshahi; Mohammad Reza Zali
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.